Ashfield Capital Partners Hosts Dinner & Discussion Event with Stanford University Bioethics Expert

January 23, 2020 | An intimate discussion on gene editing

On Wednesday, December 11, friends and clients of Ashfield Capital Partners gathered at San Francisco’s Trou Normand for a discussion on a topic that is rapidly becoming one of the most promising, complicated and controversial topics in the medical field: gene editing.

Is gene editing ethical? Is gene editing possible? Our guests got some insights into the answers to these questions as they listened to Stanford University Bioethics Professor Dr. William Hurlbut discuss the challenges and opportunities of gene editing and its scientific and ethical considerations over dinner and cocktails. 

For those interested in learning more about genome editing, we recommend reading this recent article from Bloomberg.

Keeping our clients and friends up to date with interesting and timely information related not just to investments but to every part of your life is important to us. Please stay tuned for more information about educational events from Ashfield in 2020.

 

About Dr. Hurlbut 

William B. Hurlbut is a physician and Adjunct Professor in the Department of Neurobiology at Stanford University Medical Center. His primary areas of interest involve the ethical issues associated with advanced biomedical technology, the biological basis of moral awareness, and studies in the integration of theology and philosophy of biology. He has worked with NASA on projects in astrobiology and on Chemical and Biological Warfare at Stanford’s Center for International Security and Cooperation. From 2002 – 2019, Dr. Hurlbut served on the President’s Council on Bioethics.

 

Please see some photos of the event below: